These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21487605)

  • 1. A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments.
    Seyhan AA; Varadarajan U; Choe S; Liu Y; McGraw J; Woods M; Murray S; Eckert A; Liu W; Ryan TE
    Mol Biosyst; 2011 Jun; 7(6):1974-89. PubMed ID: 21487605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.
    Seyhan AA; Varadarajan U; Choe S; Liu W; Ryan TE
    Mol Biosyst; 2012 Apr; 8(5):1553-70. PubMed ID: 22446932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
    J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
    Kunz C; Borghouts C; Buerger C; Groner B
    Mol Cancer Res; 2006 Dec; 4(12):983-98. PubMed ID: 17189388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells.
    Qu Y; Wang J; Sim MS; Liu B; Giuliano A; Barsoum J; Cui X
    Breast Cancer Res Treat; 2010 Jun; 121(2):311-21. PubMed ID: 19609669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.
    Rabindran SK; Discafani CM; Rosfjord EC; Baxter M; Floyd MB; Golas J; Hallett WA; Johnson BD; Nilakantan R; Overbeek E; Reich MF; Shen R; Shi X; Tsou HR; Wang YF; Wissner A
    Cancer Res; 2004 Jun; 64(11):3958-65. PubMed ID: 15173008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S; Huang X; Lee CK; Liu B
    Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neratinib (HKI-272) in the treatment of breast cancer.
    López-Tarruella S; Jerez Y; Márquez-Rodas I; Martín M
    Future Oncol; 2012 Jun; 8(6):671-81. PubMed ID: 22764764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.
    Xia W; Bisi J; Strum J; Liu L; Carrick K; Graham KM; Treece AL; Hardwicke MA; Dush M; Liao Q; Westlund RE; Zhao S; Bacus S; Spector NL
    Cancer Res; 2006 Feb; 66(3):1640-7. PubMed ID: 16452223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.
    Menderes G; Bonazzoli E; Bellone S; Black JD; Lopez S; Pettinella F; Masserdotti A; Zammataro L; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Med Oncol; 2017 May; 34(5):91. PubMed ID: 28397106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin fails to interfere with the antiproliferative and cytotoxic effects of antitumor drugs.
    Gewirtz DA; Di X; Walker TD; Sawyer ST
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2232-8. PubMed ID: 16609039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
    Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
    Chen X; Yeung TK; Wang Z
    Biochem Biophys Res Commun; 2000 Nov; 277(3):757-63. PubMed ID: 11062025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
    Zhang Y; Zhang J; Liu C; Du S; Feng L; Luan X; Zhang Y; Shi Y; Wang T; Wu Y; Cheng W; Meng S; Li M; Liu H
    Cancer Lett; 2016 Nov; 382(2):176-185. PubMed ID: 27597738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice.
    Aggarwal BB; Shishodia S; Takada Y; Banerjee S; Newman RA; Bueso-Ramos CE; Price JE
    Clin Cancer Res; 2005 Oct; 11(20):7490-8. PubMed ID: 16243823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
    Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.
    Wang H; Han H; Von Hoff DD
    Cancer Res; 2006 Oct; 66(19):9722-30. PubMed ID: 17018631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.